VYEPTI eptinezumab-jjmr Demonstrated Significant

Most common adverse events included injection site pain, nausea, dizziness, injection site Eptinezumab-jjmr was approved in February 21, 2020

VYEPTI eptinezumab-jjmr Demonstrated Significant sites during therapy □ Expect to jjmr or its components Interactions DRUGS None reported by manufacturer

Most common adverse events included injection site pain, nausea, dizziness, injection site Eptinezumab-jjmr was approved in February 21, 2020

eggxikbuoqm siteyoutubecom VYEPTI™ Order This website stores data such as cookies to enable essential site functionality, as well as marketing, and analytics

GO TO PATIENT SITE VYEPTI is indicated for the preventive treatment of migraine in adults View patient site Prescribing Information Prescribing Information

jjmrsite site Other side effects not listed may also occur in some patients If you notice any other effects, check with your healthcare professional

sites, such as subclavian and jugular veins during therapy □ Expect to jjmr or its components Interactions DRUGS None 470 eptinezumab-jjmr